18F-PSMA-1007 PET/CT in PSMA-Avid Bladder Urothelial Carcinoma with Extensive Bone Metastases: A Case Report

18F-PSMA-1007 PET/CT in PSMA-Avid Bladder Urothelial Carcinoma with Extensive Bone Metastases: A Case Report | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article 18 F-PSMA-1007 PET/CT in PSMA-Avid Bladder Urothelial Carcinoma with Extensive Bone Metastases: A Case Report Jie Wang, Bo Wu, Mengting Qiao, Meng Liang, Zhifang Wu This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9239371/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 5 You are reading this latest preprint version Abstract Background: PSMA PET can accurately localize PSMA-expressing lesions. However, PSMA expression is not limited to prostate cancer cells but is also widely present in the neovascular endothelial cells of various solid tumors. Case presentation: We present a case of urothelial carcinoma of the bladder with multiple bone metastases. Conclusions: This case highlights that ¹⁸F-PSMA-1007 PET/CT improved visualization of the primary bladder lesion, and demonstrates that ¹⁸F-PSMA-1007–avid osteoblastic bone metastases can originate from bladder cancer. PSMA bladder urothelial carcinoma prostate adenocarcinoma bone metastasis Figures Figure 1 Background Given the high expression of prostate-specific membrane antigen (PSMA) in malignant prostate cells, PSMA PET is an effective tool for detecting prostate cancer and its metastases. [ 1 ] However, the expression of PSMA is not limited to prostate cancer cells but is also widely present in the neovascular endothelial cells of various solid tumors, including urothelial carcinoma, glioblastoma, non-small cell lung cancer, and rectal carcinoma, etc. [ 2 – 4 ] Case presentation An 82-year-old man presented with persistent gross hematuria. Laboratory tests revealed an elevated carbohydrate antigen CA72-4 level of 37.8 U/mL (reference value, ≤ 12.1 U/mL). 18 F-FDG PET/CT was performed screening for tumors. Maximum intensity projection (MIP) images (Fig. 1 A) demonstrated multiple hypermetabolic lesions throughout the body, PET/CT fusion image identified multiple osteogenic bone lesions throughout the skeleton (SUVmax, 12.85) (Fig. 1 B, white arrow). And focal increased FDG uptake was observed in the prostate (SUVmax, 7.14) (Fig. 1 C, white arrow). No focal uptake was observed in the bladder wall because of intense FDG accumulation in the urine. (Fig. 1 D). As a result, prostate malignancy with extensive bone metastases was suggested and 18 F-PSMA-1007 PET/CT was performed. PSMA MIP images (Fig. 1 E) revealed multiple PSMA-avid lesions throughout the body and axial images (Fig. 1 F, white arrow) further confirmed extensive PSMA-avid osteoblastic bone metastases (SUVmax, 14.55). However, the prostate gland showed no abnormal PSMA uptake (Fig. 1 G) and serum TPSA level was in normal range (4.025 ng/mL). In addition, axial images of the urinary bladder (Fig. 1 H) demonstrated focal intense PSMA uptake in the left posterior bladder wall (SUVmax, 13.28, white arrow). Subsequent cystoscopic biopsy revealed scattered atypical cells within the bladder mucosal stroma. Immunohistochemical analysis showed positivity for GATA3, CK7, CK20, and p63, and negativity for prostate-specific acid phosphatase (PSAP) and NKX3.1, with HER2 expression scored as 2+, confirming the diagnosis of invasive urothelial carcinoma. Conclusions Compared with previously reported 68 Ga-PSMA-11 PET/CT imaging, 18 F-PSMA-1007 PET/CT provided a clearer urinary bladder background, allowing improved visualization of the primary bladder lesion [ 1 ] . Furthermore, ¹⁸F-PSMA-1007–avid osteoblastic bone metastases can originate from bladder cancer. [ 2 , 4 ] Abbreviations FDG Fluorodeoxyglucose PSMA Prostate-Specific Membrane Antigen PET/CT Positron Emission Tomography / Computed Tomography SUV Standardized Uptake Value Declarations Acknowledgements: This work was supported by the National Natural Science Foundation of China (General Program) [grant number 82572280]. The funding source provided financial support for the study design, data collection, and analysis regarding the role of tumor-associated fibroblasts in PET glycometabolic heterogeneity of lung cancer. Authors’ contributions: Material preparation and data collection were performed by JW, BW and MQ. The first draft of the manuscript was written by JW. ZFW and ML reviewed and edited previous versions of the manuscript. All authors read and approved the final manuscript. Funding: This work was supported by the National Natural Science Foundation of China (General Program) [grant number 82572280]. Data availability: The datasets and imaging studies supporting the findings of this case report are available from the corresponding author upon reasonable request. Ethics approval and consent to participate: This is an observational study. The Institutional Research Ethics Committee waived ethical approval. Informed consent was obtained from the participant included in the study. Consent for publication : Written informed consent was obtained from the patient for the anonymized publication of their clinical data and accompanying images. Competing interests: The authors have no relevant financial or non-financial interests to disclose. References Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. 10.1007/s00259-016-3573-4 . Zhao B, Dong A, Zuo C. Prostate-Specific Membrane Antigen-Avid Bone Metastases From Urothelial Carcinoma of the Bladder. Clin Nucl Med. 2022;47:892–4. 10.1097/RLU.0000000000004246 . Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med. 2016;41:414–6. 10.1097/RLU.0000000000001139 . Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018;59:871–7. 10.2967/jnumed.117.203570 . Cite Share Download PDF Status: Under Review Version 1 posted Reviewers agreed at journal 28 Apr, 2026 Reviewers invited by journal 21 Apr, 2026 Editor invited by journal 12 Apr, 2026 Editor assigned by journal 08 Apr, 2026 First submitted to journal 02 Apr, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9239371","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":626740598,"identity":"5fb1eea2-c88d-4f4a-b03a-d0e5320c2bbe","order_by":0,"name":"Jie Wang","email":"","orcid":"","institution":"First Hospital of Shanxi Medical University","correspondingAuthor":false,"prefix":"","firstName":"Jie","middleName":"","lastName":"Wang","suffix":""},{"id":626740599,"identity":"7a5c8e50-2976-425d-b3c9-a598f2c665c5","order_by":1,"name":"Bo Wu","email":"","orcid":"","institution":"First Hospital of Shanxi Medical University","correspondingAuthor":false,"prefix":"","firstName":"Bo","middleName":"","lastName":"Wu","suffix":""},{"id":626740600,"identity":"77092790-2765-4603-b5f1-b6f5fd624006","order_by":2,"name":"Mengting Qiao","email":"","orcid":"","institution":"First Hospital of Shanxi Medical University","correspondingAuthor":false,"prefix":"","firstName":"Mengting","middleName":"","lastName":"Qiao","suffix":""},{"id":626740601,"identity":"fad829e8-c5a0-4a82-ac6a-96f9238094c2","order_by":3,"name":"Meng Liang","email":"","orcid":"","institution":"First Hospital of Shanxi Medical University","correspondingAuthor":false,"prefix":"","firstName":"Meng","middleName":"","lastName":"Liang","suffix":""},{"id":626740602,"identity":"ffd63e02-ca4b-429a-a523-a2cb107d663e","order_by":4,"name":"Zhifang Wu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYDACCcaGD2AGewNU5ABhLY0zwAwemFLCWhgYIVokEojUIj+7ubHh547axA03nz+TutnGIMd3I4HxcwEeLYxzDjY29p45nrjhdo6xcW4bg7HkjQRm6Rl4tDBLJLY/4G07lgvUwvgYqCVxw40ENmYePFrYJBIbG/+CtNw8/uAwUEs9QS08QC3NvG01uRtuMBiCbEkwIKRFAqRFtu1A/cwzQL/knJMwnHnmYbM0Pi3yM9IfNr5tqzPmO378mXROmY083/Hkg5/xaYGCw3BbgZixgbAGBoY6YhSNglEwCkbBSAUAKTFTl/B02tkAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0003-0376-982X","institution":"First Hospital of Shanxi Medical University","correspondingAuthor":true,"prefix":"","firstName":"Zhifang","middleName":"","lastName":"Wu","suffix":""}],"badges":[],"createdAt":"2026-03-27 02:58:43","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-9239371/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9239371/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":108384297,"identity":"434606e5-b33e-4de1-a9fe-0f603492a73c","added_by":"auto","created_at":"2026-05-04 05:52:33","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":834290,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eA\u003c/strong\u003e: FDG PET/CT MIP image demonstrated multiple hypermetabolic lesions throughout the body. \u003cstrong\u003eB\u003c/strong\u003e: FDG PET/CT fusion image identified multiple osteogenic bone lesions throughout the skeleton. \u003cstrong\u003eC\u003c/strong\u003e: Focal increased FDG uptake was observed in the prostate. \u003cstrong\u003eD\u003c/strong\u003e: No focal uptake was observed in the bladder wall because of intense FDG accumulation in the urine. \u003cstrong\u003eE\u003c/strong\u003e: PSMA PET/CT MIP image revealed multiple PSMA-avid lesions throughout the body. \u003cstrong\u003eF\u003c/strong\u003e: Axial image further confirmed extensive PSMA-avid osteoblastic bone metastases. \u003cstrong\u003eG\u003c/strong\u003e: The prostate gland showed no abnormal PSMA uptake. \u003cstrong\u003eH\u003c/strong\u003e: The urinary bladder demonstrated focal intense PSMA uptake in the left posterior bladder wall.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-9239371/v1/68b904ce38a248d65c3d1332.png"},{"id":108492816,"identity":"3ddc3f59-9190-4b07-ad6a-46bbc5da79e1","added_by":"auto","created_at":"2026-05-05 09:58:43","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1232480,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9239371/v1/03d99330-760a-4490-85e1-d4aa09420d56.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003e\u003csup\u003e18\u003c/sup\u003eF-PSMA-1007 PET/CT in PSMA-Avid Bladder Urothelial Carcinoma with Extensive Bone Metastases: A Case Report\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eGiven the high expression of prostate-specific membrane antigen (PSMA) in malignant prostate cells, PSMA PET is an effective tool for detecting prostate cancer and its metastases.\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e However, the expression of PSMA is not limited to prostate cancer cells but is also widely present in the neovascular endothelial cells of various solid tumors, including urothelial carcinoma, glioblastoma, non-small cell lung cancer, and rectal carcinoma, etc.\u003csup\u003e[\u003cspan additionalcitationids=\"CR3\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e"},{"header":"Case presentation","content":"\u003cp\u003eAn 82-year-old man presented with persistent gross hematuria. Laboratory tests revealed an elevated carbohydrate antigen CA72-4 level of 37.8 U/mL (reference value, \u0026le;\u0026thinsp;12.1 U/mL). \u003csup\u003e18\u003c/sup\u003eF-FDG PET/CT was performed screening for tumors. Maximum intensity projection (MIP) images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA) demonstrated multiple hypermetabolic lesions throughout the body, PET/CT fusion image identified multiple osteogenic bone lesions throughout the skeleton (SUVmax, 12.85) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB, white arrow). And focal increased FDG uptake was observed in the prostate (SUVmax, 7.14) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC, white arrow). No focal uptake was observed in the bladder wall because of intense FDG accumulation in the urine. (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). As a result, prostate malignancy with extensive bone metastases was suggested and \u003csup\u003e18\u003c/sup\u003eF-PSMA-1007 PET/CT was performed. PSMA MIP images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE) revealed multiple PSMA-avid lesions throughout the body and axial images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF, white arrow) further confirmed extensive PSMA-avid osteoblastic bone metastases (SUVmax, 14.55). However, the prostate gland showed no abnormal PSMA uptake (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG) and serum TPSA level was in normal range (4.025 ng/mL). In addition, axial images of the urinary bladder (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eH) demonstrated focal intense PSMA uptake in the left posterior bladder wall (SUVmax, 13.28, white arrow). Subsequent cystoscopic biopsy revealed scattered atypical cells within the bladder mucosal stroma. Immunohistochemical analysis showed positivity for GATA3, CK7, CK20, and p63, and negativity for prostate-specific acid phosphatase (PSAP) and NKX3.1, with HER2 expression scored as 2+, confirming the diagnosis of invasive urothelial carcinoma.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eCompared with previously reported \u003csup\u003e68\u003c/sup\u003eGa-PSMA-11 PET/CT imaging, \u003csup\u003e18\u003c/sup\u003eF-PSMA-1007 PET/CT provided a clearer urinary bladder background, allowing improved visualization of the primary bladder lesion\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e. Furthermore, \u0026sup1;⁸F-PSMA-1007\u0026ndash;avid osteoblastic bone metastases can originate from bladder cancer.\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eFDG\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eFluorodeoxyglucose\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePSMA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eProstate-Specific Membrane Antigen\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePET/CT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ePositron Emission Tomography / Computed Tomography\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSUV\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eStandardized Uptake Value\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e This work was supported by the National Natural Science Foundation of China (General Program) [grant number 82572280]. The funding source provided financial support for the study design, data collection, and analysis regarding the role of tumor-associated fibroblasts in PET glycometabolic heterogeneity of lung cancer.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions:\u003c/strong\u003e Material preparation and data collection were performed by JW, BW and MQ. The first draft of the manuscript was written by JW. ZFW and ML reviewed and edited previous versions of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c/strong\u003e This work was supported by the National Natural Science Foundation of China (General Program) [grant number 82572280].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability:\u0026nbsp;\u003c/strong\u003eThe datasets and imaging studies supporting the findings of this case report are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u0026nbsp;\u003c/strong\u003eThis is an observational study. The Institutional Research Ethics Committee waived ethical approval. Informed consent was obtained from the participant included in the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003cstrong\u003e:\u0026nbsp;\u003c/strong\u003eWritten informed consent was obtained from the patient for the anonymized publication of their clinical data and accompanying images.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests:\u0026nbsp;\u003c/strong\u003eThe authors have no relevant financial or non-financial interests to disclose.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGiesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00259-016-3573-4\u003c/span\u003e\u003cspan address=\"10.1007/s00259-016-3573-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhao B, Dong A, Zuo C. Prostate-Specific Membrane Antigen-Avid Bone Metastases From Urothelial Carcinoma of the Bladder. Clin Nucl Med. 2022;47:892\u0026ndash;4. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/RLU.0000000000004246\u003c/span\u003e\u003cspan address=\"10.1097/RLU.0000000000004246\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med. 2016;41:414\u0026ndash;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/RLU.0000000000001139\u003c/span\u003e\u003cspan address=\"10.1097/RLU.0000000000001139\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSalas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018;59:871\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2967/jnumed.117.203570\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.117.203570\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"ejnmmi-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ejre","sideBox":"Learn more about [EJNMMI Research](http://ejnmmires.springeropen.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/ejre/default.aspx","title":"EJNMMI Research","twitterHandle":"@officialEANM","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"PSMA, bladder urothelial carcinoma, prostate adenocarcinoma, bone metastasis","lastPublishedDoi":"10.21203/rs.3.rs-9239371/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9239371/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePSMA PET can accurately localize PSMA-expressing lesions. However, PSMA expression is not limited to prostate cancer cells but is also widely present in the neovascular endothelial cells of various solid tumors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCase presentation:\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe present a case of urothelial carcinoma of the bladder with multiple bone metastases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions:\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis case highlights that ¹⁸F-PSMA-1007 PET/CT improved visualization of the primary bladder lesion, and demonstrates that ¹⁸F-PSMA-1007–avid osteoblastic bone metastases can originate from bladder cancer.\u003c/p\u003e","manuscriptTitle":"18F-PSMA-1007 PET/CT in PSMA-Avid Bladder Urothelial Carcinoma with Extensive Bone Metastases: A Case Report","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-05-04 05:52:29","doi":"10.21203/rs.3.rs-9239371/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2026-04-28T07:19:10+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-04-21T05:21:54+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"EJNMMI Research","date":"2026-04-12T13:45:55+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-04-08T08:37:57+00:00","index":"","fulltext":""},{"type":"submitted","content":"EJNMMI Research","date":"2026-04-03T02:54:25+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"ejnmmi-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ejre","sideBox":"Learn more about [EJNMMI Research](http://ejnmmires.springeropen.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/ejre/default.aspx","title":"EJNMMI Research","twitterHandle":"@officialEANM","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"6fad6fe7-3ef0-4c0f-8f43-9d14be7a255f","owner":[],"postedDate":"May 4th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-05-04T05:52:30+00:00","versionOfRecord":[],"versionCreatedAt":"2026-05-04 05:52:29","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9239371","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9239371","identity":"rs-9239371","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}